

Overview
Cancer-associated thrombosis (CAT) is one of the leading causes of morbidity and mortality in cancer
patients. The management of CAT with anticoagulation therapy has evolved over the past two decades. While
low molecular weight heparins (LMWHs) have been the standard of care, emerging evidence has demonstrated
direct oral anticoagulants (DOACs) as an effective option for the management of CAT.
In this lecture,
Professor John Eikelboom presented an overview of the treatment landscape for CAT, and reviewed current
clinical and real-world evidence for DOACs for the management of CAT. Professor Eikelboom also highlighted
current guideline recommendations and discussed considerations in choosing an appropriate anticoagulant for
venous thromboembolism (VTE) patients with cancer.
Upon completion of this module, participants will have a better understanding of the following aspects:
PP-ELI-HKG-1222 AUG 2023